Anna Maria Pugliese Selected Research

Anna Maria Pugliese Research Topics

Disease

9	Brain Ischemia (Cerebral Ischemia) 01/2022 - 08/2007
7	Ischemia 12/2020 - 09/2003
3	Chronic Pain 03/2023 - 01/2019
3	Pain (Aches) 07/2021 - 01/2019
3	Stroke (Strokes) 01/2020 - 01/2014
2	Brain Injuries (Brain Injury) 06/2021 - 02/2013
2	Demyelinating Diseases (Demyelinating Disease) 12/2020 - 01/2020
2	Neuralgia (Stump Neuralgia) 01/2020 - 01/2020
2	Alzheimer Disease (Alzheimer's Disease) 02/2015 - 09/2013
2	Bradycardia 01/2014 - 01/2006
1	Colitis 01/2022
1	Multiple Sclerosis 09/2021
1	Wounds and Injuries (Trauma) 01/2021
1	Hypertrophic Cicatrix (Hypertrophic Scar) 12/2020
1	Keloid 12/2020
1	Hypotension (Low Blood Pressure) 01/2014
1	Neuroinflammatory Diseases 01/2014
1	Ischemic Stroke 01/2014
1	Epilepsy (Aura) 12/2013
1	Seizures (Absence Seizure) 12/2013
1	Hypothermia 02/2013
1	Fever (Fevers) 02/2013
1	Hyperthermia 02/2013
1	Tachycardia (Tachyarrhythmias) 06/2006

Drug/Important Bio-Agent (IBA)

9	Adenosine (Adenocard)FDA LinkGeneric 03/2023 - 09/2007
6	Purinergic P1 Receptors (Adenosine Receptor)IBA 03/2023 - 01/2014
6	Glucose (Dextrose)FDA LinkGeneric 12/2020 - 08/2007
6	Oxygen (Dioxygen)IBA 12/2020 - 08/2007
2	N(6)- (3- iodobenzyl)- 5'- N- methylcarboxamidoadenosineIBA 01/2022 - 07/2021
2	LigandsIBA 01/2022 - 09/2021
2	Proteins (Proteins, Gene)FDA Link 07/2021 - 12/2020
2	Adenosine Triphosphate (ATP)IBA 06/2021 - 01/2016
2	DexpramipexoleIBA 06/2021 - 01/2020
2	phytobacteriomycin (PBM)IBA 01/2021 - 12/2020
2	Glutamic Acid (Glutamate)FDA Link 01/2016 - 01/2014
2	Inflammation MediatorsIBA 01/2016 - 01/2014
2	Peptides (Polypeptides)IBA 02/2015 - 09/2013
2	Amyloid (Amyloid Fibrils)IBA 02/2015 - 09/2013
2	Adenosine Monophosphate (AMP)IBA 12/2013 - 02/2013
2	Tetrodotoxin (Tetradotoxin)IBA 06/2006 - 01/2006
1	Analgesics (Analgesic Drugs)IBA 03/2023
1	Opioid Analgesics (Opioids)IBA 07/2021
1	Narcotics (Narcotic Analgesics)IBA 07/2021
1	Tissue Plasminogen Activator (Alteplase)FDA Link 05/2021
1	Carbonic Anhydrases (Carbonic Anhydrase)IBA 05/2021
1	Carbonic Anhydrase InhibitorsIBA 05/2021
1	Protective AgentsIBA 05/2021
1	CollagenIBA 12/2020
1	benzothiazoleIBA 01/2020
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2020
1	SodiumIBA 01/2020
1	Sodium Channels (Sodium Channel)IBA 01/2020
1	PyrazinesIBA 01/2017
1	diphenyl (biphenyl)IBA 01/2017
1	Neuroprotective AgentsIBA 01/2016
1	Adenosine A2A Receptor (Adenosine A2A Receptors)IBA 01/2014
1	beta-apocarotenoid-14',13'-dioxygenase (ADO)IBA 12/2013
1	Anticonvulsants (Antiepileptic Drugs)IBA 12/2013
1	NucleotidesIBA 02/2013
1	ProstaglandinsIBA 02/2013
1	5'-Nucleotidase (5' Nucleotidase)IBA 02/2013
1	Adenosine A1 ReceptorIBA 02/2013
1	Mitogen-Activated Protein KinasesIBA 06/2011
1	Purinergic P2 Receptors (ADP Receptor)IBA 06/2011
1	4- diphenylacetylamino- 2- phenylpyrazoloquinolineIBA 08/2007
1	4- dibenzoylamino- 2- (4- methoxyphenyl)pyrazoloquinolineIBA 08/2007
1	Sodium Channel BlockersIBA 06/2006
1	Methysergide (Sansert)FDA Link 06/2006
1	CopperIBA 01/2006
1	2,3- diethyl- 4,5- dipropyl- 6- phenylpyridine- 3- thiocarboxylate- 5- carboxylateIBA 09/2003
1	Purinergic P1 Receptor AntagonistsIBA 09/2003

Therapy/Procedure

3	Therapeutics 12/2020 - 01/2019
1	Physical Therapy Modalities (Physical Therapy Technique) 01/2021
1	Low-Level Light Therapy (LLLT) 01/2021
1	Aftercare (After-Treatment) 12/2020
1	Analgesia 01/2020
1	Drug Therapy (Chemotherapy) 01/2014
1	Induced Hypothermia 02/2013
1	Injections 02/2013